Cargando…

NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature

Breakpoint cluster region - Abelson (BCR-ABL1) chimeric protein and mutated Nucleophosmin (NPM1) are often present in hematological cancers, but they rarely coexist in the same disease. Both anomalies are considered founder mutations that inhibit differentiation and apoptosis, but BCR-ABL1 could act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catalano, Gianfranco, Niscola, Pasquale, Banella, Cristina, Diverio, Daniela, Trawinska, Malgorzata Monika, Fratoni, Stefano, Iazzoni, Rita, De Fabritiis, Paolo, Abruzzese, Elisabetta, Noguera, Nelida Ines
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643801/ https://www.ncbi.nlm.nih.gov/pubmed/33194157 http://dx.doi.org/10.4084/MJHID.2020.083

Ejemplares similares

Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations
por: Mariotti, Benedetta, et al.
Publicado: (2019)

Primary Pulmonary Hodgkin Lymphoma Simulating a Mediastinal Tumour: an Uncommon Occurrence
por: Fratoni, Stefano, et al.
Publicado: (2013)

Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia
por: Molica, Matteo, et al.
Publicado: (2020)

Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
por: Niscola, Pasquale, et al.
Publicado: (2013)

Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis
por: Niscola, Pasquale, et al.
Publicado: (2013)

SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection
por: Abruzzese, Elisabetta, et al.
Publicado: (2020)

Case Report: Very Late, Atypical Extra-Medullary Relapse in a Patient With Acute Promyelocytic Leukemia (APL) Rescued With a Transplant-Free Approach
por: Molica, Matteo, et al.
Publicado: (2021)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
por: Molica, Matteo, et al.
Publicado: (2020)

GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms
por: Yang, Naery, et al.
Publicado: (2018)

Minor BCR-ABL1-Positive Acute Myeloid Leukemia Associated With the NPM1 Mutation and FLT3 Internal Tandem Duplication
por: Kim, Moon Jung, et al.
Publicado: (2016)

Long-term survival of a patient with bone marrow gelatinous degeneration of idiopathic origin
por: Niscola, Pasquale, et al.
Publicado: (2012)

BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing
por: Mroczkowska-Bękarciak, Aleksandra, et al.
Publicado: (2023)

CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin
por: Molica, Matteo, et al.
Publicado: (2021)

Primary diffuse large B-cell lymphoma of the bone marrow in a frail and elderly patient successfully treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
por: Niscola, Pasquale, et al.
Publicado: (2013)

Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms
por: Morishita, Soji, et al.
Publicado: (2023)

Impact on Mental Health, Disease Management and Socioeconomic Modifications in Hematological Patients during COVID-19 Pandemia in Italy
por: De Muro, Marianna, et al.
Publicado: (2020)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
por: Barcelos, Michelle Maccarini, et al.
Publicado: (2011)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients
por: Cassinat, Bruno, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome
por: Niscola, Pasquale, et al.
Publicado: (2013)

Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent
por: Niscola, Pasquale, et al.
Publicado: (2015)

Hodgkin’s Lymphoma in a Man with Dilated Cardiomyopathy and Paraneoplastic Ataxia: A Therapeutical Challenge
por: Abruzzese, Elisabetta, et al.
Publicado: (2017)

Retrospective analysis of the clinical features of 172 patients with BCR-ABL1-negative chronic myeloproliferative neoplasms
por: Lin, Xiaolan, et al.
Publicado: (2020)

Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm
por: Abbou, Norman, et al.
Publicado: (2022)

Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?
por: Palombi, Massimiliano, et al.
Publicado: (2016)

The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms
por: Kelemen, Katalin
Publicado: (2022)

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
por: Soverini, Simona, et al.
Publicado: (2019)

Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy
por: Niscola, Pasquale, et al.
Publicado: (2014)

BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia
por: Cai, Zhimei, et al.
Publicado: (2020)

Consensus on BCR‐ABL1 reporting in chronic myeloid leukaemia in the UK
por: Cross, Nicholas C. P., et al.
Publicado: (2018)

Bone marrow involvement by primary oxalosis
por: Fratoni, Stefano, et al.
Publicado: (2020)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL–Negative Myeloproliferative Neoplasms
por: Belliere, Julie, et al.
Publicado: (2020)

The immune landscape in BCR‐ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy
por: Strickland, Marie, et al.
Publicado: (2021)

Mutational Analysis of SH2B3 in Korean Patients With BCR-ABL1 Negative Myeloproliferative Neoplasm
por: Kim, Namhee, et al.
Publicado: (2016)

Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study
por: Baek, Seung-Woo, et al.
Publicado: (2018)

Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India
por: Maddali, Madhavi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m05gibocvugm5emh3bmj87e43g